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Preface
This paper ist the fifth of a series of Recommenda-
tions on Drug Interferences and Drug Effects in Clini-
cal Chemistry. Others deal with:
Part 1. The basic concepts (1)
Part 2. Guidelines for evaluation of analytical inter-
ference (2)
Part 3. Evaluation of biological effects of drugs
Part 4. Clinical laboratory tests on laboratory ani-
mals during toxicity studies
Part 6. Laboratory tests in monitoring drug adminis-
tration
Part 7. Data banks
The published documents should be consulted prior




2. Choice and Interpretation of laboratory tests dur-
ing clinical trials
3. Factors influencing the choice and Interpretation
of laboratory tests for each phase of clinical trials
4. Conclusions and recommendations
5. References
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Table 1. Laboratory tests, useful for clinical trials
Table2. Laboratory tests, according to organs and
functions, useful for clinical trials
1. Introduction
Drugs administered during clinical trials may influ-
ence the laboratory test results observed in healthy
subjects or in patients suffering from the illness the ·
drug is intended to treat. These modifications may
result from the pharmacological action and/or toxic
effects of the drug candidate, or secondary drug
effects.
Clinical trials are studies designed to discover and
document drug efficacy and safety and to define drug
pharmacology and bioavailability (3). Such trials re-
quire careful and thorough consideration of ethical
issues governing their conduct.
Clinical trials are frequently divided into three or
four phases (4):
Phase I clinical trials enroll small numbers of healthy
volunteers or patients. Such trials define the tolerance
of a drug candidate in the ränge of doses likely to be
administered during therapy. Drug metabolism and
pharmacokinetics in human are also studied during
these trials.
Phase II clinical trials, usually conducted on up to
100 patients, allow for continued pharmacokinetic
and toxicological studies of the drug candidate, under
the specific physiological conditions induced by the
illness. This phase also aims to demonstrate pharma-
cological activity in patients suffering from the illness
the product is intended to treat and to allow an initial
assessment of the therapeutic efficacy.
Phase III clinical trials require the participation of
multiple institutions and enroll large numbers of
patients. These trials compare the drug candidate to
reference compounds of known therapeutic value or
to placebo. The purpose of these trials is to document
the efficacy of the drug candidate in comparison to
a reference compound or placebo and to document
the adverse effects caused by the drug candidate.
Phase IV clinical trials refer to studies performed
after a drug has been approved for marketing in a
particular country. These trials are designed to dis-
cover new indications, document safety and efficacy
of new formulation, and provide surveillance of a
drug äs it becomes widely available to a population.
2. Choice and Interpretation of laboratory tests during
clinical trials
2.1 Choice of laboratory tests
During clinical trials, laboratory tests are performed
with the aim of:
« l
o Assessing the initial condition of subjects who will
receive the drug candidate being studied. Labora-
tory tests, along with medical histöry, physical
examination, and ancillary clinical testing provide
criteria for selecting subjects to be enrolled in a
clinical trial (inclusion or exclusion criteria).
o Documenting the possible beneficial effect induced
by the drug candidate.
o Identifying the toxicity of the drug candidate which
then allows evaluation of the risk: benefit ratio
(risk due to therapy/benefits expected from ther-
apy).
c Identifying secondary biological effects thus con-
tributing to a better understanding of the effects
of the drug candidate in human.
These objectives guide the choice of laboratory tests
required for an individual clinical trial. Particular
attention is paid to the chemical family and pharma-
cological class of the product tested and to results
already obtained in animal toxicology studies. The
specificity5) (3) of tests and especially their sensitiv-
ity6) (4) are taken into consideration.
2.2 Performance and Interpretation of lab-
oratory tests
Correct performance of specimen collection and pro-
cessing techniques äs well äs test procedures are re-
quired to minimize sources of analytical variations,
The Interpretation of results should take both refer^
ence intervals and physiological variations into ac-
count. The results should be evaluated with appropri-
ate controls, each subject being bis own control when*
ever possible. Any significant variations observed
should be compared to observations inade during
clinical studies and preclinical toxicological studies in
animals, and to Information previously acquired on
the population under consideration (healthy or dis-
eased subjects). Test result variations caused by ana-
lytical procedures themselves (i. e., drug interference,
assay malfunction) should be taken into considera-
tion. The variations observed in relationship tö the
5) Specificity is "probability that test result will be negative
when the disease is not present"
6) Sensitivity is "probability that test result will be positive
when the disease is present"
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drug candidate's administration schedule (dose,
means of administration, duration of treatment, äs-
sociated medications...), its metabolism and its phar-
macokinetics must also be considered. It would be
useful to check the analytical interferences of the
analyte at the highest peak of drug concentration
during clinical trials.
3. Factors influencing the choice and Interpretation of
laboratory tests for each phase of clinical trials
3.1 Phase I and II
As much Information that is possible must be col-
lected during Phase I and II clinical trials in order to
define and interpret the large number of variables
observed in the population studied. The following
test profiles should be performed:
o An overall test profile designed to define the gen-
eral state of health of those volunteers included in
the study (Table 1).
o The test profile normally performed for the diag-
nosis and treatment of the disease involved (Tables
l and 2).
c Test profiles related to functions which appear to
have been influenced by the drug at the time of
the first toxicological studies in animals (Table
2), particularly hepatic and renal function profiles
which, if affected, may modify the substance's
pharmacological profile. The eventual particular
sensitivity of certain subjects (for example, children
or old persons) must be taken into consideration.
Specimens should be coljected prior to drug adminis-
tration for baseline laboratory determinations. An
aliquot of the specimens should be stored to permit
additiönal testing which may prove necessary or de-
sirable at a later date.
The frequency of felopd sämpling depends upon the
half-life of the drug candidate being studied äs deter-
mined by preclinical trials in animals and humans.
If the drag is administef ed äs a single dose, specimen
collectioii should be performed at regulär interval(s)
and should be close to the biological half-life of the
active drug (or metabolite). If the drug is admiiiis-
tered in multiple doses, successive series of samples
should be taken at regulär intervals and should de-
pend on the duration of drug administration, the
biological half-life of the active drug (metabolite)
and previous clinical laboratory data obtained. In
addition, a blood sample should be collected at half-
way through the duration of the drug administration.
A final series of specimens are collected either when
it is known that the drug or active metabolite ad-
ministered are no longer present in the subject.
Should one or more abnormal laboratory test results
be discovered, then repeat clinical laboratory as-
sessments should be performed until all abnormal
results return to control or baseline levels.
The Interpretation of results should be done accord-
ing to the rules previously stated. In particular, the
possibility of an analytical interference must be taken
into account for specimens collected when the blood
level of the active drug (or metabolite) is high (Part 2).





B-Platulocytes (Thrombocytes), number concentration






P-Activated partial thromboplastin time
Blood chemistry
P,S-Alanine aminotransferase, catalytic activity concentration
P,S-Aspartate aminotransferase, catalytic activity concentration
P,S^Alkaline phosphatase, catalytic activity concentration
P,S-y-Glutamyltransferase, catalytic activity concentration
P,S-Bilirubin, substance concentration
P,S-Cholesterol, substance concentration
(fPt) P,S-Triglyceride, substance concentration
RS-Protein, mass concentration
P,S-Albumin, mass concentratiön
(fPt) , -Glucose, substance concentration
P,S-Urate, substance concentration
P,S-Carbamide (Ürea), substance concentration
P,S-Creatininium (Creatinine), substance concentration
P,S-Sodium ion, substance concentration
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U-Acetoacetate, arbitrary concentration
U-Haemoglobin, arbitrary concentration
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Tab. 2. Laboratory tests, according to organs and functions,





B-Erythrocytes, volume fraction (Haematocrit)
B-Erythrocytes, number concentration




P-Activated partial thromboplastin time
Pt-Bleeding time
P-Fibrinogen (Mr 340000), substance concentration




P-Antithrombin III, substance concentration
P,S-Vitamin B12 (Cobalamin), substance concentration
B,S-Folates, substance concentration
Liver
P,S-Alanine aminotransferase, catalytic activity concentration
P,S-Aspartate aminotransferase, catalytic activity concentration
P,S-Bilirubin (and conjugated), substance concentration
P,S-Alkaline phosphatase, catalytic activity concentration
P,S-y-Glutamyltransferase, catalytic activity concentration
P,S-5'-nucleotidase, catalytic activity concentration
P,S-Protein, mass concentration and electrophoresis
P-Coagulation factors
P,S-Bile acids, substance concentration
Muscle
P,S-Creatine kinase (isoenzymes), catalytic activity concentra-
tion
Kidney
dU-Carbamide (Urea), substance concentration











Routine urinary cytological examination
Lipids
P,S-Cholesterol, substance concentration




P,S-Calcium (II) (Ca), substance concentration
dU-Calcium (II) (Ca), amount of substance
P,S-Phosphate (P, non-esterified), substance concentration
dU-Phosphate (P), amount of substance
P,S-Alkaline phosphatase, catalytic activity concentration





P,S-Free thyroxine, substance concentration
P,S-Triiodothyronirie, substance concentration
P,S-Free triiodothyronine, substance concentration
P,S-Prolactin, substance concentration ' f
P,S-Insulin, substance concentration
P,S-Renin/Angiotensui, substance coricentratipn
S-Growth hormone, substance concentration
Enzyme induction and pharmacogenetics
P,S-Y-Glutamyltransferase, catalytic activity concentration
dU-6ß-hydroxycörtisol, substance concentration
P,S-active drug and its metabolites, substance concentrations
Debrisoquine test (monooxygenation)
Immune function
P,S-Immunoglobin A, mass concentration
P,S-Immunoglobin G, mass concentration
P,S-Immunoglobin M, mass cöncentration
P,S-Complement (C3a, C4), mass concentrations
(T and B) Lymphocytes
Hypersensitivity
B-Eosinophil Leukocytes, number concentration
P,S-Total and specific Immunoglobulin E, mass concentrations
P,S-Anti-DNA antibodies, mass concenträtions
JP,S-Anti-drug antibodies, mass concentrations
3.2 Phase III
The selection of laboratory tests depends upon the
results previously obtained. Observation of enzyme
induction or hypersensitivity düring Phase I and II
clinical trials may necessitate the inclusion of certain
specific clinical laboratory tests düring these trials
(Table 2).
Drug interactions which could alter the metabolism
or toxicity of the drug should also be cousidered
düring the development of clinical laboratory testing
strategies.
3.3 Phase IV
Phase IV clinical trials include elements of Phase l,
II, and III clinical trials depending upon the objec-
tives set for the specific post-marketing study being
conducted. Choice of laboratory tests accordingly
will vary with the objective of the clinical triäl being
conducted and will reflect factors found to be altered
düring clinical trials,
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4. Conclusions and recommendations
To improve the effectiveness of clinical laboratory
investigations and to facilitate the dissemination of
results, the following Steps should be taken:
4.1
Summary and evaluation of clinical laboratory test
results should be performed after each clinical trial
to identify the effects of the drug studied on labora-
tory tests. Also, the evaluation should contain the
significant variations observed, the intensity and cor-
relation with subject Status (healthy volunteer or
patients categorized by disease) according to the du-
ration of treatment äs well äs drug doses administer-
ed.
4.2
Data banks should be constructed to make available
results previously obtained during clinical trials. Since
the results are of significant clinical relevance, they
should be collected and circulated to medical scien-
tists and practitioners.
4.3
Study groups should be formed to periodically review
and Update the lists of tests and their Interpretation
criteria to improve assessment of the risk to benefit
ratio. Ultimately, these study groups would assist
the development of clinical research protocols using
uniform and systematic clinical laboratory methodol-
ogy.
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1. Introduction
Information concerning the influences of drugs on
laboratory tests is large and rapidly growing and can
be found in many different scientific publications.
The amount of this Information äs well äs its variety
and wide distribution render any classification or use
of these data impossible without the aid of a Com-
puter (3,4).
1.1
Data banks are needed to get reliable Information in
a practical form.
o As relevant data must be easily and freely accessi-
ble, a data base System is best suited for storage.
o The data Information should be available interac-
tively via data terminals.
o It should be possible to include Information from
the data bank into local Computers and into
routine hospital work.
o Abstracts from the data bank may be published at
intervals. For this purpose, computerized photo-
composition or other techniques without reprint-
ing are well suited.
1.2
The following are the potential users and should be





— Professionals running registers for adverse drug
reactions
— Health educators
— Reagent and Instrument manufacturers
1.3
All drugs should be in International Nonproprietary
Name (INN) but with proprietary names available.
2. Sources of Information
2.1
Already existing literature and registers:
There are several collections of Information published
on data banks (5-11). In USA, the first data bank
on this topic was completed at the National Institutes
of Health in the 1970's (5). In Sweden, the Depart-
ment of Drugs, National Board of Health and Wei-
fare has collected and evaluated reports in SWEDIS,
the computerized Swedish drug Information System
(7, 8). It contains clinically relevant Information on
drug interferences and effects in clinical chemistry. In
France, Intermedic has been supported by "Institute
National de la Sante et de la Recherche Medicale"
and the Center for Preventive Medicine (Nancy-Van-
doeuvre). It is distributed byf Societe Francaise de
Biologie Clinique "Telemätique Systeme" and con·*
tains evaluated Information on physiological varia-
tions and drug effects (9). In Great Britain, Delta
Bank offers critically evaluated Information ön drugs
and other factors which influence the Interpretation
of diagnostic laboratory tests (10). Some Information
is currently available, internatjonally through on-line
Services, from the electronic publishers Data-Star
(11). Data bank Information can also be obtained
from the registers of drtig manufacturers, and reagent
and Instrument manufacturers.
2.2
Information and laboratory test results perforined
during toxicological studies in animals and drug trials
in humans.
2.3
Post-marketing surveillance of a drug.
2.4
Reports on side (adverse) drug reactions in routine
clinical work:
Adverse drug reactions are sometimes detected bj
laboratory tests. It is essential that the relationship
between the suspected drug and the adverse reactioi
is well documented. Adverse drug reactions are criti
cally reviewed and excellently summarized ir
"Meyler's Side Effeets of Drugs" by Dukes (12), an<
the uniform annuals of it. Another bpok containinj
importänt and well documented Information on sid<
effects of drugs is published by Davies (13). In man:
countries, adverse drug reactions are systematicall·
collected by health authorities (14).
In the fütüre, Information from INIDIS (the Inter
national Drag Information System) of the WHO Col
laborative Centre for International Drug Monitoring
may be included. This System includes at presefit
170000 reports on adverse drug reactions from 2.
countries. However, permission from WHO is neede<
before the data can be made available. One lirnitatioi
is that at present, only a smäll percentage of th
clinical cases of side effects of drugs is reported
Problems in this field have been reviewed by Co
lombo & Tognoni (l 5).
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2.5
Health examinations of patients and normal indivi-
duals.
3. Selection of reports
In order not to corrupt the data banks, it is important
to include only a reasonable amount of Information
that is reliable arid documented. The Information
should be judged by specially trained persons who
act äs an interface between published reports and
data banks. In this way, it will be possible to create
"knowledge banks."
3.1
The clinical significance of the Variation must be
proven. Quantitative aspects of drug effects on lab-
oratory test results must be considered äs discussed
by Dawkins & Salway (13).
The reports must contain documentation on:
The probability that a particular effect will occur; the
magnitude of the change induced; the precision and
if possible accuracy of the analytical methods used;
the clinical significance of the Variation found; äs well
äs the statistical methods used and how they were
adapted to the problem.
3.2
We propose that the following types of reports, when
relevant, should be stored in special data files.
o Reports concerning isolated cases. Cäses of earlier
unknown side effects must be analyzed, registered
and grouped to detect a secondary effect äffecting
only a small part of a lajge population.
o Reports concerning overdoses of drugs.
o Intended effects obtained by drug treatment (e. g.
lowering of blood glucose by insulin).
o Animal studies.
o The influence of additives (such äs ci träte, heparin
or ethylene diamine tetracetic acid* EDTA) to the
blood collection tubes.
4. General requirements of the data bank
A data base system best suited to fulfil the present
and future needs of different users concerning drug
effects in clinical chemistry must be adapted. The
following are general requirements:
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• The data base should have capability of expansion
and it could be modified without altering existing
programs.
o Different users should be able to use the existing
data in different ways, and for new purposes.
o The data bank should be capable of exchanging
Information with other Systems.
5. Contents of the data bank
General rules for acceptance and inclusion of Infor-
mation in data banks are:
• Primary publications documenting reactions to
drügs should always be preferred.
c Secondary publications should not be accepted
without valid supporting documentation. Informa-
tion about a drug in a primary literature reference
may be changed to the point of inaccuracy in
secondary literature. Therefore precautions must
be taken when including secondary Information.
Reports concerning the following types of effects of
drugs on laboratory test results should be included.
5.1
Analytical interferences (in vitro) of drugs (if possible
after administration of therapeutic doses to humans).
As stated in Part 2 "Guidelines for evaluation of
analytical interference" there are special problems
concerning in vitro interference of drugs:
o Different analytical methods are used in different
laboratories. Interferences may be of different
nature, chemical or instrumental. Also small ana-
lytical modifications may be important. Thus, a
detailed description of the techniques used must
be avaijable from the reference source.
o The analytical techniques are changing all the time,
therefore techniques should be specified.
e A metabolite or component of the excipients of a
tablet or capsule, rather.than the drug itself, may
be responsible for the effects. This is of particular
interest in urine analysis.
e Co-administration of two or more drugs may pro-
duce different interferences.
5.2
Biological effects of therapeutic doses of drugs in
vivo.
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Details are found in Part 3 "Evaluation of Biological
Effects of Drugs." Considerations must be given to:
o Effects observed regularly in humans
o Effects obtained in certain genetically sensitive
patients
o Effects due to idiosyncrasy
5.3
Drug effects on reference values and reference limits.
5.4
Clinical relevance is a priority
* In vitro experiments are not always relevant in
clinical practice (e. g., ascorbic acid affects urine
glucose determination with reduction methods
after in vitro addition but only in rare cases with
high-dose vitamin therapy).
o Many drug effects may be statistically significant
but are unlikely to be clinically relevant.
• Information for use in clinical practice should be
included in data banks.
Animal experiments can sometimes be misleading
for evahiation of drug effects in humans. They are
generally used äs predictors of toxicity.
6. Conclusions
Data banks containing clinically important informa-
tion on drug interferences and drug effects in clinical
chemistry are strongly needed due to the large num-
ber of data in this field. Information on therapeutic
drug effects on clinical laboratory tests is available
in several disciplines. It is necessary for people work>
mg in all relevant fields to learn from each other. We
certainly need collaboration between clinical chem-
ists, haematologists, pharmacologists, clinical phar-
macologists, pharmacists, drug producefs, biochem-
ists and clinicians, The task of establishing a reliable
data bank on drug interferences and effects in clinical
chemistry is enormous and world wide collaboration
is needed.
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